Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (GONO)

被引：0
|
作者：
Falcone, A.
Brunetti, I. M.
Benedetti, G.
Evangelista, W.
Picone, V.
Vitello, S.
Rosso, R.
Granetto, C.
Porcile, G.
Masi, G.
机构：
[1] Univ Study Pisa, Osped Civile, UO Oncol Med, Livorno, Italy
[2] Osped S Chiara, UO Oncol Med, Pisa, Italy
[3] Osped Bellaria, UO Oncol Med, Bologna, Italy
[4] Osped S Giovanni Molinette, COES, Turin, Italy
[5] Policlin Umberto 1, UO Oncol Med, Rome, Italy
[6] Osped S Elia, UO Oncol Med, Caltanissetta, Italy
[7] IST, Genoa, Italy
[8] Osped S Croce & Carle, SC Oncol Med, Cuneo, Italy
[9] Osped S Lazzaro, UO Oncol, Alba, Italy
[10] Osped Civile, UO Oncol Med, Livorno, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [21] Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (IR)+5-FU/LV (IRFL) followed by docetaxel (T)+5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the gruppo oncologico Nord-Ovest (G.O.N.O.)
    Loupakis, Fotios
    Masi, Gianluca
    Fontana, Eloise
    Picone, Vincenzo
    Mentuccia, Lucia
    Granetto, Cristina
    Fea, Elena
    Murr, Rita
    Brunetti, Isa
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2006, 17 : 316 - 316
  • [22] Capecitabine (C), in combination with irinotecan (I) and oxallplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (GONO)
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Antonuzzo, A.
    Chiara, S.
    Pfanner, E.
    Petrini, I.
    Barletta, M. T.
    Baldi, G. G.
    Falcone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 255 - 255
  • [23] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] FOLFOXIRI (IRINOTECAN, OXALIPLATIN, INFUSIONAL 5FU/LV) VS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS AFTER 5 YEARS FOLLOW UP AND RISK-STRATIFIED ANALYSIS
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Fornaro, L.
    Baldi, G.
    Salvatore, L.
    Stasi, I
    Brunetti, I
    Ricci, S.
    Palazzo, A.
    Pellegrino, A.
    Truscelli, K.
    Garrone, M.
    Chiara, S.
    Ribecco, A.
    Crino, L.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [25] FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis
    Falcone, A.
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Mancini, M.
    Granetto, C.
    Ribecco, A.
    Andreuccetti, M.
    Brunetti, I. M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 348 - 348
  • [26] FOLFOXIRI (IRINOTECAN, OXALIPLATIN, INFUSIONAL 5FU/LV) VS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS AFTER 5 YEARS FOLLOW UP AND RISK-STRATIFIED ANALYSIS
    Falcone, A.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Salvatore, L.
    Brunetti, I
    Fabbri, M.
    Chiara, S.
    Granetto, C.
    Ribecco, A.
    Andreuccetti, M.
    Masi, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 21 - 21
  • [27] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
  • [28] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [29] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
    Amoroso, Vito
    Ferrari, Vittorio
    Valcamonico, Francesca
    Vassalli, Lucia
    Simoncini, Edda
    Grisanti, Salvatore
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
  • [30] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
12345